Stockscreener 앱 받기
1.54
5.37%
0.05
전일 마감가:
$1.49
열려 있는:
$1.48
하루 거래량:
21,536
Relative Volume:
0.04
시가총액:
$3.35M
수익:
-
순이익/손실:
$-4.69M
주가수익비율:
-0.4162
EPS:
-3.7
순현금흐름:
$-3.81M
1주 성능:
-1.88%
1개월 성능:
-18.23%
6개월 성능:
-36.95%
1년 성능:
-45.10%
1일 변동 폭
$1.4501
$1.57
1주일 범위
$1.4501
$1.73
52주 변동 폭
$1.31
$4.42
Lixte Biotechnology Holdings Inc Stock (LIXT) Company Profile
명칭
Lixte Biotechnology Holdings Inc
전화
310 203 2902
주소
248 ROUTE 25A, EAST SETAUKET
LIXT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| LIXT | 1.5467 | 3.35M | 0 | -4.69M | -3.81M | -3.70 |
| VRTX | 449.84 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 745.43 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 590.99 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 245.91 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.45 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Lixte Biotechnology Holdings Inc 주식(LIXT)의 최신 뉴스
LIXTW (Lixte Biotechnology Holdings) Accounts Payable & Acc - GuruFocus.com
LIXT stock touches 52-week low at $1.53 amid market challenges - Investing.com Australia
Why VF Corp Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket - Benzinga
LIXT stock touches 52-week low at $1.53 amid market challenges By Investing.com - Investing.com South Africa
Lixte Biotechnology granted extension to meet Nasdaq listing rules By Investing.com - Investing.com Australia
Lixte Biotechnology granted extension to meet Nasdaq listing rules - Investing.com
Lixte Biotechnology Holdings Inc WT (LIXTW-Q) QuotePress Release - The Globe and Mail
Omeros (OMER) Shares Drop 5.04% Amid Financial Struggles - GuruFocus.com
MRVI Stock Drops 5.11% Amid Financial Report Release - GuruFocus.com
Lixte Biotechnology (NASDAQ:LIXT) Stock Price Down 2.1% - Defense World
LIfT BioSciences raises £10m in first close of Series A to advance first-in-class allogeneic innate cell therapy - GlobeNewswire
Should investors be concerned about LYT’s high price-to-sales ratio? - US Post News
Lilium (NASDAQ:LILM) Earns Overweight Rating from Cantor Fitzgerald - MarketBeat
Liquidia Co. (NASDAQ:LQDA) Shares Bought by Rhumbline Advisers - Defense World
Pacer Advisors Inc. Has $16.07 Million Stock Position in Liquidity Services, Inc. (NASDAQ:LQDT) - Defense World
Lipella Pharmaceuticals Inc’s Market Journey: Closing Weak at 0.41, Down -2.35 - The Dwinnex
Renaissance Technologies LLC Sells 2,000 Shares of LSI Industries Inc. (NASDAQ:LYTS) - Defense World
Texas Permanent School Fund Corp Trims Position in Liquidity Services, Inc. (NASDAQ:LQDT) - Defense World
First Eagle Investment Management LLC Increases Stake in LSI Industries Inc. (NASDAQ:LYTS) - Defense World
Huber Capital Management LLC Acquires 241,814 Shares of Lyft, Inc. (NASDAQ:LYFT) - Defense World
Acadian Asset Management LLC Cuts Position in LSI Industries Inc. (NASDAQ:LYTS) - Defense World
Quest Partners LLC Invests $28,000 in LSI Industries Inc. (NASDAQ:LYTS) - Defense World
Investors who lost money with shares of Liquidia Corporation - openPR
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia CorporationLQDA - Kilgore News Herald
Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing - Yahoo Finance
Biotech Steals The Show Following Pre-Clinical Data Announcement - MSN
Lixte Biotechnology Holdings Inc (LIXT) Stock: A Year of Decreases and Increases - The InvestChronicle
LIXTLixte Biotechnology Holdings, Inc. Latest Stock News & Market Updates - StockTitan
LIXTE Receives U.S. Patent Issue Notification for Immune Oncology - GlobeNewswire
Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Short Interest Update - Defense World
Why Nordstrom Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket - Benzinga
Market Recap Check: Lixte Biotechnology Holdings Inc (LIXT)’s Positive Finish at 2.00, Up/Down 11.12 - The Dwinnex
LIXT Stock: A Voyage Through Lixte Biotechnology Holdings Inc’s Finances - The InvestChronicle
LIXT stock touches 52-week low at $1.55 amid market fluctuations - Investing.com
First Patient Dosed with LIXTE’s LB-100 in New Clinical - GlobeNewswire
First Patient Dosed with Lixte Biotechnology Holdings, Inc.?s LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company - Marketscreener.com
First Patient Dosed with LIXTE’s LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company - StockTitan
Lixte Biotechnology faces Nasdaq delisting over equity shortfall - Investing.com India
LIXT (Lixte Biotechnology Holdings) PS Ratio : (As of Aug. 20, 2024) - GuruFocus.com
LIXT (Lixte Biotechnology Holdings) PS Ratio : (As of Aug. 19, 2024) - GuruFocus.com
LIXT (Lixte Biotechnology Holdings) Inventory-to-Revenue : 0.00 (As of Jun. 2024) - GuruFocus.com
LIXTE Biotechnology Provides Update On Recent Activities and Developments - ForexTV.com
LIXT (Lixte Biotechnology Holdings) Purchase Of Investment : $0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com
LIXT (Lixte Biotechnology Holdings) Owner Earnings per Shar - GuruFocus.com
LIXT (Lixte Biotechnology Holdings) COGS-to-Revenue : 0.00 (As of Jun. 2024) - GuruFocus.com
LIXT (Lixte Biotechnology Holdings) Debt-to-Equity : 0.00 (As of Jun. 2024) - GuruFocus.com
LIXT (Lixte Biotechnology Holdings) Effective Interest Rate on Debt % : 0.00% (As of Jun. 2024) - GuruFocus.com
LIXT (Lixte Biotechnology Holdings) Effect of Exchange Rate Changes : $0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com
LIXT (Lixte Biotechnology Holdings) Float Percentage Of Tot - GuruFocus.com
LIXT (Lixte Biotechnology Holdings) Interest Coverage : 0 (At Loss) (As of Jun. 2024) - GuruFocus.com
LIXT (Lixte Biotechnology Holdings) Capex-to-Revenue : 0.00 (As of Jun. 2024) - GuruFocus.com
Lixte Biotechnology Holdings Inc (LIXT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.80%
0.42%
자본화:
|
볼륨(24시간):